Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.1K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.1K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.1K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

773
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
773
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

2.2K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.2K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

584
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
584
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

324
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
324

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low versus standard dose intravenous alteplase in the treatment of acute ischemic stroke in Egyptian patients.

Neurosciences (Riyadh, Saudi Arabia)·2021
Same journal

Association Between Extracranial Artery Stenosis and Cerebral Small-Vessel Disease in Patients with Ischemic Stroke.

Neurosciences (Riyadh, Saudi Arabia)·2026
Same journal

Identifying Risk Factors for the Rising Prevalence of Multiple Sclerosis in Saudi Arabia: A case-control analysis.

Neurosciences (Riyadh, Saudi Arabia)·2026
Same journal

Novel <i>ENPP</i>1 Gene Mutation Causing Generalized Arterial Calcification of Infancy: A case report.

Neurosciences (Riyadh, Saudi Arabia)·2026
Same journal

Insights Into Stroke Risk and Prediction for Underweight Individuals.

Neurosciences (Riyadh, Saudi Arabia)·2026
Same journal

Key Attributes of an Ideal Neurology Residency Candidate: Program Directors' Perspectives.

Neurosciences (Riyadh, Saudi Arabia)·2026
Same journal

Impact of Burnout and Sleep Deprivation on the Clinical Performance of Neurology Residents: A Cross-Sectional Country Wide Study.

Neurosciences (Riyadh, Saudi Arabia)·2026
See all related articles

Related Experiment Video

Updated: Dec 14, 2025

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.4K

Angiotensin converting enzyme polymorphism and ischemic stroke.

Gelan M Salem1, Ghada K Gab-Allah

  • 1Department of Neuropsychiatry, Menoufia university, Shibin El-Kom, Egypt.

Neurosciences (Riyadh, Saudi Arabia)
|July 20, 2020
PubMed
Summary
This summary is machine-generated.

Angiotensin converting enzyme (ACE) gene polymorphism (I/D) showed variations in Egyptian ischemic stroke patients but did not significantly increase stroke risk or severity. Further research is needed to confirm its role.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.3K
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.3K

Related Experiment Videos

Last Updated: Dec 14, 2025

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.4K
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.3K
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.3K

Area of Science:

  • Genetics
  • Neurology
  • Cardiovascular Research

Background:

  • Ischemic stroke is a significant health concern.
  • The angiotensin converting enzyme (ACE) gene is a potential candidate gene for stroke risk.
  • Understanding genetic predispositions is crucial for stroke prevention.

Purpose of the Study:

  • To investigate the association between angiotensin converting enzyme (ACE) gene polymorphism and ischemic stroke in an Egyptian population.
  • To determine if ACE gene variations influence stroke severity.

Main Methods:

  • A case-control study included 70 ischemic stroke patients and 30 healthy controls.
  • Genotyping of the ACE gene polymorphism (Insertion/Deletion - I/D) was performed.
  • Neurological assessment and stroke classification (e.g., NIHSS, Toast) were conducted.

Main Results:

  • The Insertion/Deletion (I/D) polymorphism and the D allele were more frequent in ischemic stroke patients, but not significantly.
  • Different ACE genotypes (I/D, DD) were associated with specific stroke subtypes (e.g., cardioembolic).
  • No significant correlation was found between ACE gene polymorphism and National Institute of Health Stroke Scale (NIHSS) scores.

Conclusions:

  • ACE gene polymorphism (I/D) differences were observed in Egyptian ischemic stroke patients.
  • Current findings do not support ACE gene polymorphism as a significant predisposing factor for stroke occurrence or severity in this cohort.
  • Further investigation with larger sample sizes may be warranted.